How many insider trades does FilingIQ track for OMER?

FilingIQ tracks 179 Form 4 insider transactions for OMER (OMEROS CORP), covering filings from Jan 28, 2015 onwards. 3 of those were filed in the last 90 days.

Are OMER insiders net buyers or net sellers?

Across the full Form 4 history for OMER, 2 transactions (1%) were open-market purchases and 51 (28%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does OMER insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is OMER in?

OMEROS CORP (OMER) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $835.21M.

OMER insider trading

NasdaqGM Healthcare

OMEROS CORP — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

179

Last 90 days

Buys / sells

1% / 28%

Market cap

$835.21M

About OMEROS CORP

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Company website: www.omeros.com

OMER insider activity at a glance

FilingIQ has scored 179 insider transactions for OMER since Jan 28, 2015. The most recent filing in our index is dated Feb 18, 2026.

Across the full history, 2 open-market purchases and 51 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on OMER insider trades is 59.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live OMER trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for OMER?: FilingIQ tracks 179 Form 4 insider transactions for OMER (OMEROS CORP), covering filings from Jan 28, 2015 onwards. 3 of those were filed in the last 90 days.
Are OMER insiders net buyers or net sellers?: Across the full Form 4 history for OMER, 2 transactions (1%) were open-market purchases and 51 (28%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does OMER insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is OMER in?: OMEROS CORP (OMER) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $835.21M.

Methodology & sources

Every OMER insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.